Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AAV-DJ gene therapy vector
- Development stage
- Preclinical
- Lead developer
- Stanford University
- Modality
- Gene Therapies
- Administration
- Intravenous, Intravitreal, Intrathecal
01
Overview
AAV-DJ is an engineered adeno-associated virus (AAV) capsid created through DNA shuffling and directed evolution of eight wild-type AAV serotypes (AAV1, 2, 4, 5, 8, 9, avian, and bovine). It is a hybrid vector, primarily a chimera of AAV2, AAV8, and AAV9, designed to exhibit superior liver transduction efficiency and resistance to neutralization by human antibodies (IVIG). Originally developed at Stanford University, it is widely used as a research tool and a platform for gene therapy delivery across various tissues, including the liver, retina, and central nervous system. The vector's unique capsid structure differs from AAV2 by 60 amino acids, providing enhanced tissue penetration and immune evasion properties.
- Other names
- AAV-DJ capsidAAV-DJ vector
02
Targets
Adeno-associated virus serotype 2 and 3 neutralizing antibodiesHSPG (Basement membrane-specific heparan sulfate proteoglycan core protein (perlecan))
Beyond the preview
Go deeper on AAV-DJ gene therapy vector.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AAV-DJ gene therapy vector.